AGEN
Agenus IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$137.42M
P/E Ratio
1.61
EPS
$2.05
Beta
1.54
52W High
$7.34
52W Low
$2.71
50-Day MA
$3.71
200-Day MA
$3.75
Dividend Yield
—
Profit Margin
52.20%
Forward P/E
1.46
PEG Ratio
1.44
About Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | $123.87M |
| Gross Profit (TTM) | $120.64M |
| EBITDA | $15.19M |
| Operating Margin | 44.60% |
| Return on Equity | -1279.00% |
| Return on Assets | 2.53% |
| Revenue/Share (TTM) | $3.74 |
| Book Value | $-5.74 |
| Price-to-Book | 218.61 |
| Price-to-Sales (TTM) | 1.11 |
| EV/Revenue | 1.155 |
| EV/EBITDA | 1.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 40.20% |
| Shares Outstanding | $41.64M |
| Float | $38.86M |
| % Insiders | 6.70% |
| % Institutions | 23.46% |
Historical Volatility
HV 10-Day
74.43%
HV 20-Day
74.94%
HV 30-Day
83.93%
HV 60-Day
87.76%
HV Rank
43.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
2
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026